Spanish-language pump training aims to close diabetes tech gap for latino youth
NCT ID NCT07720388
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial tests whether a culturally tailored, Spanish-language onboarding and support program helps Latino youth aged 10–20 with type 1 diabetes adopt and consistently use the Medtronic MiniMed 780G automated insulin delivery system. Participants receive one-on-one nutrition support, a pump start class in Spanish, and regular virtual check-ins over eight months. The study asks whether this approach can improve technology adoption and health outcomes in a group that often faces barriers to using advanced diabetes devices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Culturally and linguistically tailored onboarding and support program for the Medtronic MiniMed 780G system
- What this could lead to
- If successful, this approach could help close the gap in technology adoption and improve blood sugar control in Latino youth with type 1 diabetes.
- What could go wrong
- This is a very small pilot study with only 15 participants, so results may not apply broadly. The program requires significant time and commitment from families.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Davis Center
Aurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.